ABCB1 and hepatocellular carcinoma: Mechanistically, miR-122 modulates the sensitivity of cells to doxorubicin through downregulation of MDR-related genes, ABCB1 and ABCF2, and inhibits HCC growth by inducing cell cycle arrest [68].